Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Sign Up to like & getrecommendations! Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofad205
Abstract: Abstract We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling… read more here.
Keywords: secondary infections; coronavirus disease; treatment coronavirus; reduction secondary ... See more keywords